Navigation Links
Cardium Announces $6.0 Million Registered Direct Offering
Date:10/15/2009

SAN DIEGO, Oct. 15 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced a registered direct offering of common stock to selected investors for aggregate gross proceeds of $6.0 million. The offering is made pursuant to a registration statement that was filed by Cardium Therapeutics with the Securities and Exchange Commission (the "SEC") and declared effective by the SEC on August 15, 2007. Details concerning the terms of the financing and the warrants can be found in the Company's Current Report on Form 8-K to be filed with the SEC at www.sec.gov.

(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

The securities in the offering include an estimated 4,615,385 shares of Cardium common stock at a price of $1.30 and warrants to purchase up to 3,000,000 shares of Cardium common stock at an exercise price of $1.40. The warrants are exercisable six months after the date of issuance, and will expire six years from the date they are first exercisable. Dawson James Securities acted as exclusive placement agent for the offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any offer will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

About Cardium

Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetizations. Cardium's investment portfolio includes the Tissue Repair Company and Cardium Biologics, medical technology companies primarily focused on the development of innovative therapeutic products for tissue repair and cardiovascular indications. In October 2009, Cardium announced results for the Matrix Phase 2b clinical study of the Excellarate product candidate as a treatment for patients with non-healing diabetic ulcers. News from Cardium is located at www.cardiumthx.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that the MATRIX study or other human clinical trials can be conducted and completed in an efficient and successful manner, that product formulation enhancements will be successful or will effectively simplify or expand the use of product candidates or technologies, that the GAM technology can be successfully broadened or applied to additional wound healing or tissue repair opportunities, that Excellarate or our other candidates will prove to be sufficiently safe and effective, that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures, that clinical studies even if successful will lead to product advancement or partnering, that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive, that FDA or other regulatory clearances or other certifications, or other commercialization efforts will be successful or will effectively enhance our businesses or their market value, that our products or product candidates will prove to be sufficiently safe and effective after introduction into a broader patient population, or that third parties on whom we depend will perform as anticipated.

Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2009 Cardium Therapeutics, Inc. All rights reserved.

For Terms of Use Privacy Policy, please visit www.cardiumthx.com.

Cardium Therapeutics(TM) and Generx® are trademarks of Cardium Therapeutics, Inc.

Tissue Repair(TM), Gene Activated Matrix(TM), GAM(TM), Excellarate(TM) and Osteorate(TM)

are trademarks of Tissue Repair Company.

Other trademarks are the property of their respective owners.

SOURCE Cardium Therapeutics


'/>"/>
SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. An international first at the CHUM - Promising treatment in regeneration of the myocardium through the use of stem cells
2. Cardium Reports on Recent Highlights and Financial Results
3. Cardiums InnerCool Therapies Unit Announces Australian Distribution Agreement for CoolBlue and Rapid Blue Systems
4. Cardium Announces InnerCools Endovascular Cooling to be Featured on Science Channels Series Cool Stuff: How It Works
5. Cardium Completes $6.0 Million Financing
6. Cardium Announces Investor Presentation and Corporate Update Webcast
7. Cardium Reports on New York Citys Adoption of Therapeutic Cooling Protocols for Cardiac Arrest Patients
8. Cardium Reports on Exchange Listing With NYSE Alternext US
9. Cardiums InnerCool Announces Launch of New Enhanced Website
10. Cardiums InnerCool Reports on Expanding Use of Therapeutic Hypothermia
11. Cardiums Exchange Listing Compliance Plan Accepted by NYSE Alternext US
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2018)... Mich. (PRWEB) , ... August 07, 2018 , ... Sussex ... partnered with Blue Sky Vision. Michael Sussex, OD, founded the practice in Coldwater, and ... Sussex practices with Matt Austin, OD, to offer comprehensive eye health services for patients ...
(Date:8/7/2018)... ... August 07, 2018 , ... The American Psychiatric Nurses ... receive the 2018 Board of Directors Student Scholarship . The APNA student ... health nursing and develop the next generation of leaders in the profession. ...
(Date:8/3/2018)... ... 03, 2018 , ... On August 2, 2018 the JPML ordered that the ... Sadaka Associates, LLC has been litigating Zostavax injuries since 2011. ... Multidistrict Litigation for the thousands of people injured by Zostavax, a vaccine given to ...
(Date:8/3/2018)... ... , ... Lucyd Pte Ltd, the developer of an eShop ... online store. The Lucyd eShop will feature the latest technologies and trends in ... The eShop will have a number of unique benefits over other eyewear shops, ...
(Date:8/2/2018)... ... August 02, 2018 , ... ... image e-sharing platform to connect clinicians inside and outside the network to vital ... stroke or trauma. , AHN joins other leading hospital systems nationwide in using ...
Breaking Medicine News(10 mins):
(Date:8/7/2018)... ... August 07, 2018 , ... ... demand for spinal fusion alternatives, has begun training and certifying spine physicians across ... first of fourteen physicians received training at the Weill Cornell Brain and Spine ...
(Date:8/3/2018)... N.J. (PRWEB) , ... August 03, 2018 , ... Flexefits, ... for passing H.R. 6199, especially for its allowing participants in Direct Primary Care arrangements ... covered by HSAs (capped at $150 per individual and $300 per family per month.) ...
(Date:8/2/2018)... ... ... What: The Wharton School is pleased to invite business journalists to ... business reporters who cover aspects of public policy to attend the Wharton Seminars ... covers the cost of tuition, course materials, most group meals, lodging for three nights ...
Breaking Medicine Technology: